Do antibodies to the hepatitis G virus E2 antigen in immunoglobulin products reduce infectivity?
Cristiano
K
K
Bisso
G
G
Wirz
M
M
Gentili
G
G
D004340:Drug Contamination; D006508:Hepatitis Antibodies / Q000097:blood*; D018963:Hepatitis Antigens / Q000276:immunology*; D006525:Hepatitis, Viral, Human / Q000517:prevention & control*; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology*; D016756:Immunoglobulins, Intravenous / Q000276:immunology*; D008562:Membrane Glycoproteins / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology*
D006508:Hepatitis Antibodies; D018963:Hepatitis Antigens; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D008562:Membrane Glycoproteins; D014759:Viral Envelope Proteins; C107619:glycoprotein E2, GB virus C